Cardiovascular & Metabolic
Cardiometabolic conditions, heart failure, atherosclerotic vascular disease, diabetes, obesity, and endocrine disorders.
Core & active disease programs
Hypertension
$347.4B+ attributable cost
$34.5B$+ drug spend
48 assets · 2 indications
Type 2 Diabetes
$324.6B attributable cost
$126.1B$ drug spend
145 assets · 1 indication
Obesity
$199.1B attributable cost
$21.2B$ drug spend
117 assets · 1 indication
Atherosclerotic Cardiovascular Disease
$69.5B attributable cost
$22.7B$ drug spend
116 assets · 1 indication
Heart Failure
$27.7B+ attributable cost
76 assets · 5 indications
Provisional & emerging programs (21)Early clinical pipeline & single-asset indications
Cardiovascular Disease / Dyslipidemia
Type 1 Diabetes
Severe Hypertriglyceridemia
Homozygous Familial Hypercholesterolemia
Hypertrophic Cardiomyopathy
Dyslipidemia
Familial Chylomicronemia Syndrome
Cushing's Syndrome
Mixed Hyperlipidemia
Venous Thromboembolism
Diabetes / Hypoglycemia
Growth Hormone Deficiency
Hypoparathyroidism
Hypothalamic Obesity
Congenital Adrenal Hyperplasia
Hyperinsulinemic Hypoglycemia
Hyperlipidemia
Hypoplastic Left Heart Syndrome
Male Hypogonadism
Vascular Trauma
Peripheral Artery Disease